Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Burger, AL; Bonderman, D; Brath, H; Delle-Karth, G; Greisenegger, S; Hengstenberg, C; Schlager, O; Sourij, H; Zirlik, A; Huber, K.
Reduction of residual cardiovascular risk through therapy with omega-3 fatty acids: Icosapent-ethyl in an interdisciplinary approach
J KARDIOL. 2024; 31(3-4):
Web of Science

 

Co-authors Med Uni Graz

Sourij Harald

Zirlik Andreas

Altmetrics:

Abstract:

Patients with established atherosclerotic cardiovascular disease (ASCVD) or those with type-2 diabetes mellitus (T2D) and additional risk factors need a careful control of their cardiovascular risk profile to prevent ischemic complications. Despite thorough treatment of these factors, the risk of ischemic events remains high due to the residual cardiovascular risk. Hypertriglyceridemia may be an important contributor and might help to identify patients who could benefit from additional riskreducing therapy beyond the control of low-density lipoprotein-cholesterol, antidiabetic medication, and blood- pressure management. The randomized, double -blind REDUCE-IT study investigated the potential benefit of Icosapent-ethyl (IPE) treatment in patients at high cardiovascular risk (ASCVD or T2D and additional risk factor) with elevated triglycerides (135-499 mg/dL) under statin-treatment. After a median follow-up of 4.9 years, the primary endpoint (cardiovascular death, non -fatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina or coronary revascularisation) was significantly reduced. In addition, a significant reduction of cardiovascular mortality, myo cardial infarctions and strokes were observed. This positive treatment effect was independent from the plasma levels of triglycerides before and after treatment initiation. Regarding adverse events, a higher risk of atrial fibrillation and an associated increased hospitalization rate was observed under IPE treatment. Severe bleeding complications tended to be higher in the IPE group (not statistically significant) but were not associated with fatal bleeding complications or an increased risk of hemorrhagic strokes. On the basis of this data, the treatment option with IPE was already included in the guidelines of international societies (European Society of Cardiology, American Stroke Association). J Kardiol 2024; 31 (3-4): 64-7.

Find related publications in this database (Keywords)

Icosapent-ethyl

atherosclerotic cardiovascular disease

type-2 diabetes mellitus

REDUCE-IT study

© Med Uni Graz • Imprint